Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
February 16, 2026 Off

New ECCO data show subcutaneous (SC) infliximab (Remsima™  SC) effectively recaptures and maintains disease control after drug holiday

By BusinessWire

A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC)…

February 16, 2026 Off

Galderma Announces Appointment of New Chief Financial Officer

By BusinessWire

Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland–(BUSINESS WIRE)–Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today…

February 16, 2026 Off

Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease

By BusinessWire

– MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at…

February 16, 2026 Off

Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

By GlobeNewswire

SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) — Sapu Bioscience today announced advancements in its global IP portfolio supporting…

February 14, 2026 Off

BioRestorative Announces Closing of $5.0 Million Public Offering

By GlobeNewswire

MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage…

February 14, 2026 Off

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

By GlobeNewswire

The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world’s most advanced…

February 14, 2026 Off

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

By GlobeNewswire

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented…

February 14, 2026 Off

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

By GlobeNewswire

Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Mr. Willard has a 30+…

February 14, 2026 Off

Inotiv Provides Notice Regarding Cybersecurity Incident

By GlobeNewswire

WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract…

February 14, 2026 Off

Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results

By GlobeNewswire

CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and…

Posts pagination

Previous 1 … 10 11 12 … 6,330 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine